Incomplete Susac syndrome exacerbated after natalizumab

por Zhovtis Ryerson, Lana, Kister, Ilya, Snuderl, Matija, Magro, Cynthia, Bielekova, Bibiana
Publicado 2015

Pharmacodynamics of natalizumab extended interval dosing in MS

por Zhovtis Ryerson, Lana, Li, Xiaochun, Goldberg, Judith D., Hoyt, Tamara, Christensen, Angel, Metzger, Ryan R., Kister, Ilya, Foley, John
Publicado 2020

Outcomes of COVID-19 infection in multiple sclerosis and related conditions: One-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC)

por Klineova, Sylvia, Harel, Asaff, Straus Farber, Rebecca, DeAngelis, Tracy, Zhang, Yinan, Hentz, Roland, Leung, Tung Ming, Fong, Kathryn, Smith, Tyler, Blanck, Richard, Zhovtis-Ryerson, Lana
Publicado 2021

COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center

por Parrotta, Erica, Kister, Ilya, Charvet, Leigh, Sammarco, Carrie, Saha, Valerie, Charlson, Robert Erik, Howard, Jonathan, Gutman, Josef Maxwell, Gottesman, Malcolm, Abou-Fayssal, Nada, Wolintz, Robyn, Keilson, Marshall, Fernandez-Carbonell, Cristina, Krupp, Lauren B., Zhovtis Ryerson, Lana
Publicado 2020

Cellular and Humoral Immunity to SARS‐CoV‐2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease‐Modifying Therapies: A Multi‐Ethnic Observational Study...

por Kister, Ilya, Patskovsky, Yury, Curtin, Ryan, Pei, Jinglan, Perdomo, Katherine, Rimler, Zoe, Voloshyna, Iryna, Samanovic, Marie I., Cornelius, Amber R., Velmurugu, Yogambigai, Nyovanie, Samantha, Kim, Joseph J., Tardio, Ethan, Bacon, Tamar E., Zhovtis Ryerson, Lana, Raut, Pranil, Pedotti, Rosetta, Hawker, Kathleen, Raposo, Catarina, Priest, Jessica, Cabatingan, Mark, Winger, Ryan C., Mulligan, Mark J., Krogsgaard, Michelle, Silverman, Gregg J.
Publicado 2022